Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Blood Plasma Therapy”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Study completedNCT01572480
What this trial is testing

Carfilzomib, Lenalidomide, and Dexamethasone for Smoldering Multiple Myeloma

Who this might be right for
Multiple Myeloma
National Cancer Institute (NCI) 55
Testing effectiveness (Phase 2)Study completedNCT00322842
What this trial is testing

Treatment With AMD3100 (Plerixafor) in Non-Hodgkin's Lymphoma and Multiple Myeloma Patients

Who this might be right for
Lymphoma, Non-HodgkinMultiple Myeloma
Genzyme, a Sanofi Company 35
Large-scale testing (Phase 3)Looking for participantsNCT06182774
What this trial is testing

Fixed Duration vs Continuous Anti-CD38 Antibody Therapy Among Transplant Ineligible Older Adults With Newly-Diagnosed Multiple Myeloma

Who this might be right for
Multiple Myeloma
Canadian Cancer Trials Group 570
Testing effectiveness (Phase 2)Looking for participantsNCT05776979
What this trial is testing

Post-Transplant Maintenance Therapy With Isatuximab Plus Lenalidomide for High-Risk Multiple Myeloma Patients

Who this might be right for
Multiple Myeloma
M.D. Anderson Cancer Center 61
Very early researchLooking for participantsNCT04657861
What this trial is testing

APRIL CAR-T Cell Therapy for Patients With BCMA/TACI Positive Relapsed and/or Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma in RelapseMultiple Myeloma, Refractory
Zhejiang University 36
Not applicableNot Yet RecruitingNCT06472479
What this trial is testing

LCAR-M61S and LCAR-M61D in Treatment of Relapsed/Refractory Multiple Myeloma

Who this might be right for
Relapsed/Refractory Multiple Myeloma
The First Affiliated Hospital with Nanjing Medical University 66
Not applicableNot Yet RecruitingNCT06330896
What this trial is testing

Disease Characteristics and Treatment Response in Plasma Cell Disorders Patients Based on Genetic Abnormalities From Fluorescence In Situ Hybridization and Next Generation Sequencing

Who this might be right for
Plasma Cell Disorder
Siriraj Hospital 498
Not applicableStudy completedNCT04328662
What this trial is testing

Ninlaro in Real World Clinical Practice in China

Who this might be right for
Multiple MyelomaNeoplasms, Plasma Cell
Takeda 482
Testing effectiveness (Phase 2)Active Not RecruitingNCT04497961
What this trial is testing

Health-Related Quality of Life in People With Multiple Myeloma Receiving Daratumumab or Lenalidomide

Who this might be right for
Multiple Myeloma
Memorial Sloan Kettering Cancer Center 95
Testing effectiveness (Phase 2)Study completedNCT00006890
What this trial is testing

Thalidomide and Prednisone Following Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma

Who this might be right for
Multiple Myeloma and Plasma Cell Neoplasm
NCIC Clinical Trials Group 67
Post-approval studies (Phase 4)Study completedNCT00782197
What this trial is testing

Autologous Plasma Rich in Growth Factors (PRGF) Treating the Symptomatic Knee OA

Who this might be right for
Joint Disease
Biotechnology Institute IMASD 240
Testing effectiveness (Phase 2)Study completedNCT03439280
What this trial is testing

Investigate the Safety, Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of TAK-079 Administered Subcutaneously as a Single Agent in Participants With Relapsed/Refractory (r/r) Multiple Myeloma (MM)

Who this might be right for
Relapsed/RefractoryMultiple Myeloma
Millennium Pharmaceuticals, Inc. 50
Testing effectiveness (Phase 2)WithdrawnNCT01269203
What this trial is testing

Efficacy of NF-kB Inhibition for Reducing Symptoms During Maintenance Therapy in Multiple Myeloma Patients

Who this might be right for
Multiple Myeloma
M.D. Anderson Cancer Center
Testing effectiveness (Phase 2)Study completedNCT02441686
What this trial is testing

Phase II Study of Efficacy and Safety of Lenalidomide, Subcutaneous Bortezomib and Dexamethasone Therapy for Newly Diagnosed Multiple Myeloma

Who this might be right for
Multiple Myeloma
Dana-Farber Cancer Institute 46
Early research (Phase 1)Study completedNCT04322292
What this trial is testing

BCMA-directed CAR-T Cells Treatment in Subjects With r/r Multiple Myeloma

Who this might be right for
Multiple Myeloma
Institute of Hematology & Blood Diseases Hospital, China 9
Not applicableStudy completedNCT04379752
What this trial is testing

Cold Plasma to Treat Hair Loss

Who this might be right for
Androgenetic Alopecia
Dr. Peter C. Friedman 14
Not applicableStudy completedNCT07551271
What this trial is testing

Clinical Study of PRP in the Treatment of Androgenetic Alopecia

Who this might be right for
Androgenetic Alopecia (AGA)
The First Affiliated Hospital of Soochow University 30
Early research (Phase 1)Study completedNCT02519452
What this trial is testing

Daratumumab With the Addition of Recombinant Human Hyaluronidase (rHuPH20) for the Treatment of Participants With Relapsed or Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
Janssen Research & Development, LLC 120
Very early researchNot Yet RecruitingNCT06986434
What this trial is testing

CAR19BCMA CAR-T Cells for the Treatment of R/R Plasma Cell Neoplasms and Lymphomas/Leukemias With Plasmacytic Differentiation

Who this might be right for
Relapsed or Refractory Plasma Cell NeoplasmsLymphomas/Leukemias With Plasmacytic Differentiation
Affiliated Hospital to Academy of Military Medical Sciences 20
Not applicableLooking for participantsNCT07514052
What this trial is testing

Predicting Response to Selinexor-Based Therapy in Relapsed/Refractory Multiple Myeloma: A Multicenter Prospective Study

Who this might be right for
Multiple Myeloma of Bone
Shanxi Bethune Hospital 127
Next Page